Aldeyra Therapeutics Announces Positive Top-Line Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap, an Investigational New Drug, Compared to Xiidra®
Retrieved on:
Tuesday, January 11, 2022
Research, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Optical, Science, Oncology, Other Science, Securities Exchange Act of 1934, Eye, LinkedIn, Financial condition report, Private Securities Litigation Reform Act, SEC, Patient, Tears, Temperature, U.S. Securities and Exchange Commission, Therapy, Compte rendu, Duane syndrome, Prevalence, PMID, Risk, Ophthalmology, Clinical trial, COVID-19, Inflammation, Safety, Humidity, Disease, ACE inhibitor, Retinitis pigmentosa, Nasdaq, Marketing, Topical medication, Allergic conjunctivitis, Dry eye syndrome, Multimedia, Failure, Lubrication, Annual report, Dry, Irritation, Growth, Pain, RASP, United, Biomarker, Result, Toxicity, Conversation, Medicine, Lipid peroxidation, Psoriasis, Quality of life, Analysis, Stephanie White de Goede, Asthma, Twitter, Security (finance), Physician, Pharmaceutical industry, Facebook, Lifitegrast
The double-masked, crossover, single-center, Phase 2 clinical trial in 56 dry eye disease patients evaluated the activity of reproxalap compared to Xiidra for two endpoints: ocular discomfort symptom score and ocular itching symptom score.
Key Points:
- The double-masked, crossover, single-center, Phase 2 clinical trial in 56 dry eye disease patients evaluated the activity of reproxalap compared to Xiidra for two endpoints: ocular discomfort symptom score and ocular itching symptom score.
- Symptoms were assessed approximately 15 minutes prior to chamber entry, and every 5 minutes beginning 5 minutes after chamber entry.
- Reproxalap is in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis.
- Expression of Lipid Peroxidation Markers in the Tear Film and Ocular Surface of Patients with Non-Sjogren Syndrome: Potential Biomarkers for Dry Eye Disease.